newsfilter
← Latest News
GlobeNewswire·

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance